Results 241 to 250 of about 837,409 (288)

Designing antibodies as therapeutics

Cell, 2022
Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit ...
Paul J. Carter, Arvind Rajpal
openaire   +2 more sources

Designer and Catalytic Antibodies

New England Journal of Medicine, 1990
A HUMAN being possesses on the order of 1 trillion (1012) B cells, capable of making more than 10 million different antibodies. Tapping this vast resource for clinical purposes is an important but technically challenging endeavor. The production of hybridomas makes it feasible to manufacture large quantities of monoclonal antibodies, and in principle ...
Jane F. Desforges, Ruth D. Mayforth, José Quintáns   +2 more
openaire   +2 more sources

Computational design of antibodies

Current Opinion in Structural Biology, 2018
Antibody design aims to create new antibodies with biological activity that can be used in therapy and research. Traditional methods for antibody discovery, such as animal immunization and large-scale library screening, generate antibodies that bind to the target of interest, but do not necessarily have the desired functional effect.
Sharon, Fischman, Yanay, Ofran
openaire   +2 more sources

Human antibodies by design

Nature Biotechnology, 1998
Monoclonal antibodies (Mabs) have long been considered a good class of natural drugs, both because they mimic their natural role in the body and because they have no inherent toxicity. Although rodent Mabs are readily generated, their widespread use as therapeutic agents has been hampered because they are recognized as foreign by the patient. Evidently,
T J, Vaughan, J K, Osbourn, P R, Tempest
openaire   +2 more sources

Toward rational antibody design: recent advancements in molecular dynamics simulations

International Immunology, 2018
Because antibodies have become an important therapeutic tool, rational antibody design is a challenging issue involving various science and technology fields.
Takefumi Yamashita, Yamashita Takefumi
exaly   +2 more sources

Phospho-specific antibodies by design

Nature Biotechnology, 2013
Antibodies specific to phosphorylated peptides are readily generated through structure-based engineering and in vitro selection.
Oda Stoevesandt, Michael J Taussig
openaire   +2 more sources

Designing Two-In-One Antibodies

Immunotherapy, 2009
Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years.
Ignacio Garcia, Valladares, Luis R, Espinoza   +1 more
openaire   +2 more sources

Designing antibodies for oncology

Cancer and Metastasis Reviews, 2005
The past five years have witnessed the emergence of monoclonal antibodies as important therapeutics for cancer treatment. Lower toxicity for antibodies versus small molecules, the potential for increased efficacy by conjugation to radioisotopes and cellular toxins, or the ability to exploit immune cell functions have led to clinical performances on par
openaire   +2 more sources

Clinical issues in antibody design

Trends in Biotechnology, 1995
Antibody genes can now be cloned and expressed in various ways to give new versions of antibodies that possess reduced immunogenicity, improved affinity, altered size, increased avidity and novel effector functions. The task for any clinical application is, first, to define a relevant target, and then to design the optimal antibody-based therapeutic ...
K A, Chester, R E, Hawkins
openaire   +2 more sources